Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Cerca in Study Connect

Recruiting

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants - IM027-1012

Aggiornato: 7 marzo, 2025   |   ClinicalTrials.gov.

Stampi il riassunto semplice

STA PRENDENDO IN CONSIDERAZIONE QUESTA SPERIMENTAZIONE?
Stampi questa pagina e la guida alla sperimentazione da utilizzare come supporto nel colloquio con il Suo medico.
Utilizzi la Guida per i partecipanti allo studio per esplorare il processo di partecipazione a una sperimentazione clinica. Comprenda i fattori chiave da considerare prima di decidere e pensi alle domande da porre al Suo team di professionisti sanitari.

Dettagli della sperimentazione

  • Phase 1

    Fase

  • Sesso

  • 18-55

    Fascia d'età

  • 2

    Sede/i

  • Recruiting

Opzioni di trattamento

Bracci dello studio
INTERVENTO ASSEGNATO
Experimental: Part A
Drug: BMS-986278, Placebo
Experimental: Part B1/B2 Treatment A
Drug: BMS-986278
Experimental: Part B1/B2 Treatment B
Drug: BMS-986278, Placebo
Experimental: Part B1/B2 Treatment C
Drug: Placebo
Experimental: Part B1/B2 Treatment D
Drug: Placebo, Moxifloxacin
Experimental: Part B3 Treatment A
Drug: BMS-986278
Experimental: Part B3 Treatment B
Drug: BMS-986278, Placebo
Experimental: Part B3 Treatment C
Drug: Placebo
Experimental: Part B3 Treatment D
Drug: Placebo, Moxifloxacin

Principali criteri di idoneità

Inclusion Criteria: - Female individuals not of childbearing potential (INOCBP) and males. - Healthy as determined by medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory assessments. - Body mass index (BMI) 18.0 to 32.0 kg/m2 , inclusive, for Parts A and B. Exclusion Criteria: - Any significant acute or chronic medical illness as determined by the investigator. - History of clinically relevant cardiac disease as determined by the investigator, symptomatic or asymptomatic arrhythmias, presyncope or syncopal episodes, or additional risk factors for ventricular arrhythmias. - Any significant history of disease of the cardiovascular system that in the opinion of the Investigator makes the participant unsuitable for enrollment into the study. - Other protocol-defined inclusion/exclusion criteria apply.

Ti consigliamo vivamente di contattare BMS per segnalare gli effetti collaterali (eventi avversi)
Qui vengono definiti gli effetti collaterali (eventi avversi) e altri eventi da segnalare
Segnala effetti collaterali (eventi avversi) o reclami sulla qualità del prodotto: informazioni mediche